Chapter 3: The Proof

The human trial began in November. Maren had asked Pavle to assign someone else to the first-pass analysis — she couldn't be objective about her partner's data, and she'd rather be honest about that than pretend otherwise. Pavle had said, "Nobody at this Institute is objective about anything. That's not actually how science works." But he assigned Lenka Voss, and Maren felt more honest.

Lenka Voss sent the first checkpoint results to the full staff list at 6:47 on a Wednesday morning. Maren was already awake. She'd been awake since four — Tomas had been sleeping badly for weeks, turning and turning, and his restlessness had migrated to her side of the bed the way body heat does, through proximity and time.

Maren read the data at her kitchen table while Tomas slept. The apartment was dark except for the screen. She could hear his breathing from the bedroom, uneven, catching at the turns.

The results were good. Not ambiguous-good, which would have bought everyone time. Good in the way that closes a question. Eighty-four percent correction on the targeted pathway. Subjects reporting sharper cognition, improved sleep. Every measured metric trending where Kassar predicted.

And one result that didn't fit. Two subjects showing improved inflammatory markers in gut-associated lymphoid tissue — a pathway nobody had targeted, with no obvious connection to BDNF methylation. Lenka had flagged it with a question mark: "artifact?"

Maren circled the question mark with her pen. Wrote "not artifact" in the margin. Set the pen down.

She cracked two eggs into a pan that was already too hot and ate them standing at the counter, the yolk still runny on the fork. Through the window the limestone shelves were dusted with frost and the oaks were bare. A maintenance truck crossed the lower courtyard, its engine a low diesel grumble that she could feel through the kitchen floor.

The Velden team sent their six-month follow-up two weeks later.

This time the scope was broader: all eighty-seven residents, full epigenetic panels. Still observational, still small. The kind of data any reviewer would reach for a red pen over.

Maren ran the adult data on a Saturday afternoon. Her lower back was stiff from three hours in the same chair. A half-eaten bowl of lentil soup sat cold by her keyboard. Josip was across the lab pretending to work on his own project and actually reading over her shoulder. He'd given up on subtlety weeks ago.

The dose-response curve was clean. More years of exertion, more epigenetic normalization. The data was getting harder to dismiss.

"The myokine panel is extraordinary," he said.

"You're reading my screen."

"I'm reading your screen. The myokine panel is extraordinary."

It was. But it was the sleep architecture data that made Maren lean forward until her stiff back protested. The Velden adults were sleeping differently. Not just better — structurally differently. Slow-wave phases longer. REM cycling more regular. Cortisol patterns shifted to a curve she'd only ever seen in studies of pre-industrial populations.

Nobody had a model for why cranking water pumps would change sleep architecture. No targeted pathway. No mechanism.

"These people are sleeping like it's 1200 AD," Josip said from behind her.

"Stop reading my screen."

"Their gut flora is doing the same thing. Diversification rate faster than five years should produce." He took a sip from his thermos. "I don't have a model either."

He set the thermos down. "I'm going to need better data to publish anything. But I'm going to spend the next month pretending I didn't see what I just saw."

Kassar published in March. Meticulous paper, favorable review. The twelve pathways were responding. The intervention worked.

Davorka published the same month, different journal. Hedged with limitations. But the results were there — multi-system improvement, including markers Kassar's trial hadn't measured. Because nobody had thought to.

Maren read both papers on the same day. She put one down and picked up the other. Her tea went cold on the desk.

The board meeting happened in April. Josip told her about it afterward while they walked the perimeter path through the olive grove. The olives were terrible. Nobody harvested them.

"They want to expand," Josip said. "Both sides."

"Expand what?"

"Everything." He kicked a stone off the path. "Kassar wants sixty subjects, five years, dedicated labs. Davorka wants a second settlement — two hundred people, purpose-built, ten-year funding." He paused. "And the Institute can't fund both."

"Can it fund one?"

"Barely. Pavle said something about not being able to split the baby." Josip made a face. "I don't think he enjoyed saying it."

"What was the vote?"

"There wasn't one. Pavle tabled it. He asked both sides to present revised proposals at the June meeting with realistic budgets and implementation timelines. He's hoping someone will compromise."

"Will they?"

Josip picked an olive from a low branch, looked at it, and put it back. "You can't put a clean room in a forge."

It had started to rain. Light rain, not committed. The path came out near the weather station, still measuring, still sending.

"Josip."

"Yes."

"How did you vote? At the trial meeting."

"I voted yes."

"Why?"

"Because the science was sound and the protocol was careful. The same reason you were going to vote yes before you didn't."

"And now?"

He didn't answer for a while. Rain ticked on the olive leaves.

"The trial's sound. The data's good. And Velden is —" He stopped. Picked another olive, turned it in his fingers. "Velden makes the trial look like it's measuring the wrong things. Both of those are true and I don't know what to do with that."

"Nobody does."

"Petrič does."

"Davorka always knows what to do. That's not the same as being right."

He smiled without conceding anything. "The June meeting is going to be difficult."

They walked back through the rain.

Maren found Tomas in the expression lab that evening. He was wiping down the micropipette station. It was already clean. The lab smelled like ethanol and calibration fluid and the faint ozone of the sequencing machines.

"The board tabled the expansion vote," she said.

"I heard." He didn't look up.

"Josip says they can't fund both."

"Josip is correct."

She leaned against the doorframe. The fluorescent lights buzzed. The sequencing machines hummed — steady, continuous, the sound of instruments that never needed to rest.

"Your trial is working, Tomas."

He set the cloth down. "Yes."

"And Velden is working."

"Velden is producing observational data from a self-selected community of eighty-seven idealists. That's not the same as working."

"The sleep architecture data."

"Is interesting and unexplained and doesn't prove what Davorka wants it to prove."

"What does she want it to prove?"

He looked at her. He was tired. Worse than angry — tired.

"She wants it to prove we're unnecessary. That the body just — fixes itself, if you let it." He stopped wiping. "And maybe she's right. But 'maybe' is not a research program."

"What about the things you can't see?"

Somewhere in the building, a door closed.

"That's Davorka's question," he said. "I notice you're asking it now."

"I haven't decided anything," she said.

"I know." He picked up the cloth. "But you keep asking her questions, Maren. At some point that's the same as —" He didn't finish. He didn't need to.

She stood in the doorway. Rain on the windows. The hum of the machines. A pipe ticking somewhere as it cooled.

She went home. Tomas stayed at the lab.